Skip to content

US · PAHC · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Phibro Animal Health Corporation (PAHC) intrinsic value and stock valuation

$33.29as of 2026-11-21 · Mkt cap 1.46B

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Phibro Animal Health Corporation DCF and intrinsic value

InvestorsCraft values PAHC with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from PAHC’s statements →

Phibro Animal Health Corporation Graham Number

Graham Number: $13.75d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Teaneck, NJ 07666-6712 pahc.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$1.3B+10.1% 5y CAGRd
20112025
Net income
$48.3M+7.5% 5y CAGRd
20112025
Free cash flow
$41.8M+10.6% 5y CAGRd
20112025
Total equity
$285.7M+8.7% 5y CAGRd
20072025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$1.3B$1.02B$977.9M$942.3M$833.4M
Operating income$110.5M$53.3M$71.9M$79M$74.9M
Net income$48.3M$2.42M$32.6M$49.2M$54.4M
EPSd$1.19M$59.7K$805.2K$1.21M$1.34M
Operating cash flow$80.1M$87.6M$13.3M$31.7M$48.3M
Capital expenditure-$-38.29M-$-41.24M-$-51.79M-$-37.04M-$-29.32M
Free cash flow$41.8M$46.4M-$-38.48M-$-5.39M$19M
Total assets$1.36B$982.2M$971.4M$931.7M$841.3M
Total debt$761.6M$525.5M$510M$470.5M$426.7M
Net debt$693.5M$454.9M$468.7M$396.2M$376.5M
Total equity$285.7M$256.6M$282.5M$262.4M$238.5M
Cash and short-term investments$77M$114.6M$81.3M$91.3M$93.2M
Income statement
20252024202320222021
Revenue$1.3B$1.02B$977.9M$942.3M$833.4M
Cost of revenue$896.3M$704.6M$679.7M$656.9M$562M
Gross profit$399.9M$313.1M$298.2M$285.4M$271.4M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$289.5M$259.8M$226.4M$206.4M$196.5M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$289.5M$259.8M$226.4M$206.4M$196.5M
Cost and expenses$1.19B$964.4M$906M$863.3M$758.5M
Interest income$2.62M$4.47M$3.35M$820K$840K
Interest expense$33.3M$22M$18M$12.1M$10.4M
Depreciation and amortization$45.6M$36.2M$34M$32.7M$31.9M
Ebitda$146.9M$69.1M$106M$117.1M$110.2M
Operating income$110.5M$53.3M$71.9M$79M$74.9M
Total other income/expenses, net-$-42.47M-$-42.4M-$-17.78M-$-6.66M-$-8.4M
Income before tax$68M$10.9M$54.1M$72.3M$66.5M
Income tax expense$19.7M$8.5M$21.5M$23.2M$12.1M
Net income$48.3M$2.42M$32.6M$49.2M$54.4M
Weighted average shares outstanding$40.5M$40.5M$40.5M$40.5M$40.5M
Weighted average diluted shares outstanding$40.7M$40.5M$40.5M$40.5M$40.5M
Balance sheet
20252024202320222021
Cash and short-term investments$77M$114.6M$81.3M$91.3M$93.2M
Net receivables$228M$169.5M$163.5M$166.5M$146.9M
Inventory$444.4M$265.9M$277.6M$259.2M$216.3M
Total current assets$810.6M$601M$585.7M$566.2M$498.9M
Property, plant and equipment, net$396M$240.9M$231.3M$203.2M$187.7M
Goodwill and intangible assets$96.1M$99.6M$108.3M$117.1M$115M
Long-term investments$11.7M$11.5M$11.1M$10.4M$10.1M
Total non-current assets$550.3M$381.2M$385.7M$365.5M$342.4M
Total assets$1.36B$982.2M$971.4M$931.7M$841.3M
Accounts payable$138.2M$85.6M$73.9M$95.6M$68.4M
Short-term debt$25.4M$37.3M$28.4M$21.1M$16M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$293.5M$204.2M$176M$190.8M$164.1M
Long-term debt$736.2M$488.2M$481.6M$449.4M$410.7M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$781.8M$521.4M$512.9M$478.4M$438.7M
Capital lease obligations$42.9M$37.4M$35.1M$37.6M$34.6M
Total liabilities$1.08B$725.5M$688.9M$669.3M$602.8M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings$272.7M$243.9M$260.9M$247.8M$218M
Accumulated other comprehensive income (loss)-$-124.02M-$-123.53M-$-114.21M-$-121.11M-$-115.29M
Total equity$285.7M$256.6M$282.5M$262.4M$238.5M
Total investments$20.7M$55.5M$51.1M$27.4M$53.1M
Total debt$761.6M$525.5M$510M$470.5M$426.7M
Net debt$693.5M$454.9M$468.7M$396.2M$376.5M
Cash flow statement
20252024202320222021
Net income$48.3M$2.42M$32.6M$49.2M$54.4M
Depreciation and amortization$45.6M$36.2M$34M$32.7M$31.9M
Stock-based compensation$720K$470K$0.00$0.00$1.13M
Change in working capital-$-21.56M$33.1M-$-41.13M-$-44.64M-$-29.87M
Accounts receivable-$-55.21M-$-8.68M$5.33M-$-23.62M-$-18.21M
Inventory-$-44.29M$2.64M-$-11.22M-$-47M-$-12.5M
Accounts payable$45.6M$12M-$-22.83M$26.4M$3.18M
Net cash provided by operating activities$80.1M$87.6M$13.3M$31.7M$48.3M
Investments in property, plant and equipment-$-38.29M-$-41.24M-$-51.79M-$-37.04M-$-29.32M
Acquisitions, net-$-286.53M-$-3.28M$0.00-$-13.51M$29.3M
Net cash used for investing activities-$-288.69M-$-48.19M-$-74.02M-$-22.58M-$-18.58M
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid-$-19.45M-$-19.44M-$-19.44M-$-19.44M-$-19.43M
Net cash used for financing activities$207.1M-$-6.77M$27M$16.3M-$-17M
Net change in cash-$-2.57M$29.3M-$-32.97M$24M$13.9M
Cash at end of period$68M$70.6M$41.3M$74.3M$50.2M
Operating cash flow$80.1M$87.6M$13.3M$31.7M$48.3M
Capital expenditure-$-38.29M-$-41.24M-$-51.79M-$-37.04M-$-29.32M
Free cash flow$41.8M$46.4M-$-38.48M-$-5.39M$19M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Phibro Animal Health Corporation

        Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.

        CEO
        Daniel Bendheim
        Employees
        2.48K
        Beta
        0.46

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Phibro Animal Health Corporation (PAHC)?

        Phibro Animal Health Corporation (PAHC) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PAHC undervalued?

        PAHC trades at a price of $33.29 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.